Schwartz Jonathan David's Form 4 filing
Rocket Pharmaceuticals, Inc. (RCKT) · filed Feb 27, 2025
- Accession no.
- 0001140361-25-006272
- Filed
- Feb 27, 2025
- Trade date
- May 17, 2024-Feb 25, 2025
- Filing delay
- 286 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions. Open-market sales total $224.0K. It was filed 286 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schwartz Jonathan DavidCIK 0001726398 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 17, 2024 | Common Stock | SSaleDisposed | −2,754 | $23.35 | −$64,305.9 | 169,659 | Direct | |
| Aug 16, 2024 | Common Stock | SSaleDisposed | −2,710 | $18.50 | −$50,135 | 166,949 | Direct | |
| Nov 21, 2024 | Common Stock | SSaleDisposed | −3,097 | $13.05 | −$40,415.85 | 163,852 | Direct | |
| Feb 25, 2025 | Common Stock | SSaleDisposed | −6,532 | $10.58 | −$69,108.56 | 237,638 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Chief Medical & Gene Therapy Officer